Establishment Labs Holdings Inc.

Good afternoon and welcome to Establishment Lab's first quarter 2025 earnings conference call. At this time, all participants are in a listening mode. At the end of the call, we will open the line for questions and answer sessions and instructions will follow at that time. As a reminder, today's call is being recorded. I'll now turn it over to Raj Dhanoi, Chief Financial Officer. Thank you. You may begin.

Thank you, operator, and thank you everyone for joining us. With me today is Peter Caldini, our chief executive officer, and Juan Jose Chacon Quiroz, our founder, former CEO, and a member of our board of directors. Following our prepared remarks, we'll take your questions. Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meanings of federal securities laws. These include statements on Establishment Labs' financial outlook and the company's plans and timing for product development and sales. These forward-looking statements are based on management's current expectations and involve risks and uncertainties. For discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage you to view our most recent annual and quarterly reports on Form 10-K and Form 10-Q, as well as other SSC filings, which are available on our website at EstablishmentLabs.com. I'd also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including but not limited to sales results, which can be stated on a constant currency basis, or profitability of the company's business, which can be stated as EBITDA or adjusted EBITDA. Reconciliations to comparable GAAP financial measures for non-GAAP measures, if available, may be found in today's press release, which is available on our website. The content of this conference call contains time-sensitive information accurate only as of the date of this live broadcast, May 7th, 2025. Except as required by law, Establishment Labs undertakes no obligation to revise or otherwise update any statement to reflect events or circumstances after the date of this call. With that, it is my pleasure to turn the call over to our founder, Juan Jose.

Thank you, Raj. Along with our first quarter earnings, We also announced today the appointment of Peter Caldini as permanent CEO of Establishment Labs. Since my retirement was announced in January, the board of director has undergone an extensive review of potential candidates. And following that process, the board was unanimous in their endorsement of Peter to take the role of CEO. Peter is the right CEO at the right time for our company. As a founder and CEO for the past 20 years, I've seen our company evolve from an idea that could revolutionize breast aesthetics and reconstruction by prioritizing science and data to where we are today. We've grown that idea to a suite of products and technologies with unmatched clinical performance. Our products are available globally. And we've moved the industry into a new era by making the implants better and safer and by bringing new technologies and techniques like minimally invasive to market. The next phase of growth needs a steady hand to help us achieve the financial potential of what we have put into motion. With healthy growth for many years to come, our task now is to reach profitability. Peter's experience running large multinational organizations over the past 25 years, as well as the seamless way he has become an important member of our management team, made the choice for the board quite easy. As I have said before, I am not going anywhere. I'm going to continue to work tirelessly for Establishment Labs in the role that has always been my first love, working with plastic surgeons to elevate the specialty, strategizing the launch of new products and techniques, supporting our R&D to make even greater strides, and advocating for a company to be a leader for women's health. I'm proud of the team at Establishment Labs, and I am excited for Peter to lead our organization in this next chapter of our story. With both Peter and Raj, as well as other members of our management team, I look forward to seeing you on June 12th at our Investor Day in New York City. Peter, I will turn it over to you.